Basal Marker ΔNp63α Is Enriched in Pancreatic Cancer Metastases but Not in Primary Tumors Post‐Chemotherapy
Daniel H. Ryan, Yuuki Ohara, Michael J. Kruhlak, Xianyu Zhang, Miao Lin, Chin‐Hsien Tai, Christine Alewine · 2026
Read Basal Marker ΔNp63α Is Enriched in Pancreatic Cancer Metastases but Not in Primary Tumors Post‐Chemotherapy by Daniel H. Ryan, Yuuki Ohara, Michael J. Kruhlak, Xianyu Zhang, Miao Lin, Chin‐Hsien Tai, Christine Alewine (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13669542.txt.
Description
Daniel Ryan and co-authors tested whether pancreatic cancer's tougher subtype spreads more readily, in a 2026 study. Tumors mix two programs, classical and basal; basal-heavy ones resist drugs and kill sooner. The team forced two classical cell lines to switch on the basal driver gene, then watched growth, drug response, and spread in dishes and in mice.
The switch worked on paper, flipping the cells' gene profile, yet growth and drug resistance did not budge in culture. In mice, lung metastases nonetheless carried far more of the basal marker than the home tumors did, even in control cells. Spread itself seems to select for the basal state. The hint reframes where treatment should aim.
Catalog record
| CREATOR | Daniel H. Ryan, Yuuki Ohara, Michael J. Kruhlak, Xianyu Zhang, Miao Lin, Chin‐Hsien Tai, Christine Alewine |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |